BR100 Decreased By (-1.08%)
BR30 Decreased By (-1.23%)
KSE100 Decreased By (-0.85%)
KSE30 Decreased By (-1.61%)
AGHA 6.11 Decreased By ▼ -0.07 (-1.13%)
BECO 4.12 Decreased By ▼ -0.11 (-2.6%)
BML 61.59 Decreased By ▼ -0.25 (-0.4%)
BOP 30.94 Decreased By ▼ -0.76 (-2.4%)
CNERGY 12.10 Increased By ▲ 0.04 (0.33%)
CSIL 5.65 Increased By ▲ 0.02 (0.36%)
FCCL 58.05 Decreased By ▼ -0.66 (-1.12%)
FFL 13.35 Decreased By ▼ -0.12 (-0.89%)
FNEL 1.16 Decreased By ▼ -0.01 (-0.85%)
KEL 6.11 Decreased By ▼ -0.03 (-0.49%)
KOSM 5.61 Decreased By ▼ -0.05 (-0.88%)
LOTCHEM 24.43 Decreased By ▼ -0.39 (-1.57%)
MLCF 100.04 Decreased By ▼ -2.05 (-2.01%)
NBP 175.92 Decreased By ▼ -3.74 (-2.08%)
NCPL 51.73 Increased By ▲ 1.68 (3.36%)
NPL 53.95 Increased By ▲ 1.05 (1.98%)
OGDC 312.89 Decreased By ▼ -3.35 (-1.06%)
PACE 9.22 Increased By ▲ 0.01 (0.11%)
PAEL 33.48 Decreased By ▼ -0.54 (-1.59%)
PIBTL 13.19 Decreased By ▼ -0.23 (-1.71%)
PPL 217.96 Decreased By ▼ -3.34 (-1.51%)
PRL 85.55 Increased By ▲ 0.95 (1.12%)
PTC 47.64 Decreased By ▼ -0.74 (-1.53%)
SSGC 22.60 Decreased By ▼ -0.34 (-1.48%)
TBL 9.16 Decreased By ▼ -0.14 (-1.51%)
TELE 7.15 Increased By ▲ 0.08 (1.13%)
TPL 25.48 Decreased By ▼ -0.38 (-1.47%)
TPLP 13.36 Increased By ▲ 0.25 (1.91%)
TREET 24.56 Decreased By ▼ -0.43 (-1.72%)
TRG 53.41 Decreased By ▼ -0.62 (-1.15%)
World

Norway will not offer AstraZeneca COVID-19 vaccine to people over 65

  • The FHI said there had been few participants above the age of 65 in the trial conducted by AstraZeneca, meaning there was a lack of documentation as to the effect of the vaccine on older age groups.
Published Updated
By

OSLO: Norway will not offer the AstraZeneca vaccine against COVID-19 to individuals over the age of 65, the Norwegian Institute of Public Health (FHI) said on Thursday, making it the latest European country to restrict its use.

So far, some 135,000 individuals in Norway have received their first dose against the disease and some 35,000 have received their second shot, from vaccines made by Moderna and from a partnership between Pfizer and BioNTech, the agency said.

The FHI said there had been few participants above the age of 65 in the trial conducted by AstraZeneca, meaning there was a lack of documentation as to the effect of the vaccine on older age groups.

The Nordic country has 5.4 million inhabitants.

Comments

Comments are closed for this article.